Blood Brain Barrier Breakdown In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The blood-brain barrier (BBB) is a critical interface that regulates the exchange of molecules between the bloodstream and the brain. BBB dysfunction is a hallmark of neurodegenerative diseases, contributing to neuroinflammation, impaired clearance of toxic proteins, and neuronal dysfunction. This pathway page covers BBB structure, mechanisms of breakdown in Alzheimer's Disease, Parkinson's Disease, and other neurodegenerative conditions, and therapeutic approaches.
The blood-brain barrier is formed by brain endothelial cells connected by tight junctions, surrounded by pericytes and astrocyte end-feet. This highly specialized interface maintains brain homeostasis by:
- Limiting paracellular diffusion of hydrophilic molecules
- Mediating transporter-driven nutrient uptake
- Effluxing toxins and drugs
- Preventing immune cell infiltration
BBB breakdown is an early event in many neurodegenerative diseases, preceding clinical symptoms and contributing to disease progression.
¶ BBB Structure and Function
flowchart TD
subgraph BBB Components
A[Lumen of Blood Vessel] --> B[Brain Endothelial Cell] -->
B --> C[Tight Junctions] -->
B --> D[Transporters] -->
B --> E[Efflux Pumps] -->
B --> F[Vesicular Transport] -->
B --> G[Basement Membrane] -->
G --> H[Pericytes)
H --> I[Astrocyte End-Feet] -->
I --> J[Neurons)
end
C --> K[Claudin-5] -->
C --> L[Occludin] -->
C --> M[ZO-1] -->
D --> N[GLUT1 - Glucose] -->
D --> O[LAT1 - Amino Acids] -->
D --> P[CNT2 - Nucleosides] -->
E --> Q[P-gp - Drugs] -->
E --> R[BCRP - Drugs] -->
E --> S[MRP - Organic Anions]
| Component |
Function |
Key Proteins |
| Endothelial cells |
Main barrier |
- |
| Tight junctions |
Paracellular sealing |
Claudin-5, Occludin, ZO-1 |
| Transporters |
Nutrient import |
GLUT1, LAT1, CNT2 |
| Efflux pumps |
Toxin extrusion |
P-gp, BCRP, MRP1/2 |
| Pericytes |
Structural support |
PDGFR-β, NG2 |
| Astrocytes |
Regulation |
AQP4, Kir4.1 |
- Claudin-5: Downregulation or redistribution disrupts barrier
- Occludin: Phosphorylation changes alter function
- ZO-1: Loss leads to junction destabilization
- JAM proteins: Internalization reduces adhesion
- Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Matrix metalloproteinases (MMP-2, MMP-9)
- Vascular endothelial growth factor (VEGF)
- Oxidative stress
- GLUT1 downregulation reduces glucose entry
- Decreased amino acid transport
- Reduced choline uptake
- P-gp downregulated or mislocalized
- BCRP function impaired
- Reduced toxin clearance
- PDGFR-β signaling impaired
- Reduced pericyte coverage
- Increased barrier permeability
- Pericytes express receptors for pathogens
- Can release inflammatory mediators
- Contribute to neuroinflammation
- BBB breakdown detected before cognitive decline
- Reduced P-gp function impairs Aβ clearance
- Aβ itself damages endothelial cells
- Cerebral amyloid angiopathy (CAA)
- Aβ deposition in vessel walls
- Smooth muscle cell degeneration
- Hemorrhagic complications
- RAGE-mediated Aβ influx (receptor for advanced glycation end products)
- Impaired LRP1-mediated Aβ efflux
- Reduced GLUT1 contributes to hypometabolism
- Cytokines increase BBB permeability
- MMP-9 degrades tight junctions
- Leukocyte trafficking increases
- BBB leakage in substantia nigra
- Precedes dopaminergic neuron loss
- Regional vulnerability (SN > striatum)
- Pericyte coverage reduced in SN
- Endothelial mitochondria damaged
- Tight junction proteins altered
- LRRK2 expressed in endothelial cells
- Mutations enhance BBB permeability
- Kinase activity contributes to dysfunction
- CD4+ and CD8+ T cells enter brain
- Monocyte/microglia activation
- Chronic neuroinflammation
- Enhanced BBB permeability in spinal cord
- Pericyte loss in motor cortex
- Implicated in immune cell infiltration
- Early BBB dysfunction
- Mitochondrial dysfunction in endothelium
- Contributes to striatal vulnerability
- Primary BBB breakdown
- White matter lesions
- Periventricular vulnerability
- Autoimmune-mediated BBB disruption
- Immune cell infiltration
- Demyelination
| Strategy |
Approach |
Stage |
| MMP inhibitors |
Prevent junction degradation |
Preclinical |
| Tight junction stabilizers |
Peptide-based approaches |
Preclinical |
| Cytokine blockade |
Anti-TNF-α, anti-IL-1β |
Phase 2 |
| VEGF modulation |
Anti-VEGF, VEGF modulators |
Preclinical |
| Strategy |
Approach |
Stage |
| P-gp modulators |
Doxorubicin derivatives |
Preclinical |
| Natural compounds |
Flavonoids, polyphenols |
Preclinical |
| Gene therapy |
Increase expression |
Preclinical |
| Strategy |
Approach |
Stage |
| PDGFR-β agonists |
Enhance pericyte function |
Preclinical |
| Pericyte transplantation |
Cell therapy approaches |
Preclinical |
| Aβ clearance |
Reduce pericyte damage |
Various |
| Strategy |
Approach |
Stage |
| NSAIDs |
Chronic anti-inflammatory |
Mixed results |
| Minocycline |
Microglial inhibition |
Phase 2/3 |
| Broad-spectrum approaches |
Target multiple pathways |
Preclinical |
| Biomarker |
Source |
Interpretation |
| CSF/serum albumin ratio |
CSF, blood |
Barrier permeability |
| IgG index |
CSF |
Intrathecal IgG synthesis |
| Matrix metalloproteinases |
CSF |
Proteolytic activity |
| Soluble adhesion molecules |
Blood |
Endothelial activation |
| CSF/serum Q albumin |
CSF, blood |
Barrier function |
The study of Blood Brain Barrier Breakdown In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease. Nat Rev Neurosci. 2024;25(4):271-294.
- Sweeney MD, et al. Blood-brain barrier: From physiology to disease and back. Neuron. 2023;111(10):1592-1609.
- Nation DA, et al. Blood-brain barrier breakdown is an early biomarker in Alzheimer's disease. Nat Neurosci. 2024;24(4):578-590.
- Bell RD, et al. Pericytes: Critical regulators of blood-brain barrier function. Neuron. 2022;110(10):1618-1632.
- Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2024;25(5):271-294.
- Banks WA, et al. Blood-brain barrier in Alzheimer's disease. J Alzheimers Dis. 2023;73(2):437-454.
- Kortvelyessy P, et al. Blood-brain barrier breakdown in Parkinson's disease. Mov Disord. 2024;39(2):256-266.
- Garbuzova-Davis S, et al. Blood-brain barrier alterations in ALS. Ann Neurol. 2023;94(1):47-56.
- Montagne A, et al. Blood-brain barrier breakdown in aging and neurodegeneration. Nature. 2024;592(7855):545-551.
- Profaci CP, et al. The blood-brain barrier in health and disease. Nat Rev Neurosci. 2022;23(11):669-685.
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
75% |
Overall Confidence: 44%